Skip to main content

Comprehensive analysis of cytoskeleton regulatory genes identifies ezrin as a prognostic marker and molecular target in acute myeloid leukemia

Cellular Oncology volume 44, pages 1105–1117 (2021)Cite this article

Abstract

Purpose

Despite great advances that have been made in the understanding of the molecular complexity of acute myeloid leukemia (AML), very little has been translated into new therapies. Here, we set out to investigate the impact of cytoskeleton regulatory genes on clinical outcomes and their potential as therapeutic targets in AML.

Methods

Gene expression and clinical data were retrieved from The Cancer Genome Atlas (TCGA) AML study and used for survival and functional genomics analyses. For pharmacological tests, AML cells were exposed to ezrin (EZR) inhibitors and submitted to several cellular and molecular assays.

Results

High EZR expression was identified as an independent marker of worse outcomes in AML patients from the TCGA cohort (p < 0.05). Functional genomics analyses suggested that EZR contributes to responses to stimuli and signal transduction pathways in leukemia cells. EZR pharmacological inhibition with NSC305787 and NSC668394 reduced viability, proliferation, autonomous clonal growth, and cell cycle progression in AML cells (p < 0.05). NSC305787 had a greater potency and efficiency than NSC668394 in leukemia models. At the molecular level, EZR inhibitors reduced EZR, S6 ribosomal protein and 4EBP1 phosphorylation, and induced PARP1 cleavage in AML cells. NSC305787, but not NSC668394, favored a gene network involving cell cycle arrest and apoptosis in Kasumi 1 AML cells.

Conclusions

From our data we conclude that EZR expression may serve as a prognostic factor in AML. Our preclinical findings indicate that ezrin inhibitors may be employed as a putative novel class of AML targeting drugs.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price includes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Data availability

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Code availability

Not applicable.

References

  1. H. Dohner, D.J. Weisdorf, C.D. Bloomfield, Acute myeloid leukemia. N. Engl. J. Med. 373, 1136–1152 (2015)

    PubMed  Article  CAS  Google Scholar 

  2. X. Zhao, Y. Li, H. Wu, A novel scoring system for acute myeloid leukemia risk assessment based on the expression levels of six genes. Int. J. Mol. Med. 42, 1495–1507 (2018)

    CAS  PubMed  PubMed Central  Google Scholar 

  3. T.J. Ley, C. Miller, L. Ding, B.J. Raphael, A.J. Mungall, A. Robertson, K. Hoadley, T.J. Triche Jr., P.W. Laird, J.D. Baty, L.L. Fulton, R. Fulton, S.E. Heath, J. Kalicki-Veizer, C. Kandoth, J.M. Klco, D.C. Koboldt, K.L. Kanchi, S. Kulkarni, T.L. Lamprecht, D.E. Larson, L. Lin, C. Lu, M.D. McLellan, J.F. McMichael, J. Payton, H. Schmidt, D.H. Spencer, M.H. Tomasson, J.W. Wallis, L.D. Wartman, M.A. Watson, J. Welch, M.C. Wendl, A. Ally, M. Balasundaram, I. Birol, Y. Butterfield, R. Chiu, A. Chu, E. Chuah, H.J. Chun, R. Corbett, N. Dhalla, R. Guin, A. He, C. Hirst, M. Hirst, R.A. Holt, S. Jones, A. Karsan, D. Lee, H.I. Li, M.A. Marra, M. Mayo, R.A. Moore, K. Mungall, J. Parker, E. Pleasance, P. Plettner, J. Schein, D. Stoll, L. Swanson, A. Tam, N. Thiessen, R. Varhol, N. Wye, Y. Zhao, S. Gabriel, G. Getz, C. Sougnez, L. Zou, M.D. Leiserson, F. Vandin, H.T. Wu, F. Applebaum, S.B. Baylin, R. Akbani, B.M. Broom, K. Chen, T.C. Motter, K. Nguyen, J.N. Weinstein, N. Zhang, M.L. Ferguson, C. Adams, A. Black, J. Bowen, J. Gastier-Foster, T. Grossman, T. Lichtenberg, L. Wise, T. Davidsen, J.A. Demchok, K.R. Shaw, M. Sheth, H.J. Sofia, L. Yang, J.R. Downing, G. Eley, Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059–2074 (2013)

    PubMed  Article  CAS  Google Scholar 

  4. F. Mollinedo, C. Gajate, Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 8, 413–450 (2003)

    CAS  PubMed  Article  Google Scholar 

  5. E. Nogales, Structural insight into microtubule function. Annu. Rev. Biophys. Biomol. Struct. 30, 397–420 (2001)

    CAS  PubMed  Article  Google Scholar 

  6. M. Hesse, T.M. Magin, K. Weber, Genes for intermediate filament proteins and the draft sequence of the human genome: novel keratin genes and a surprisingly high number of pseudogenes related to keratin genes 8 and 18. J. Cell Sci. 114, 2569–2575 (2001)

    CAS  PubMed  Article  Google Scholar 

  7. I. Szeverenyi, A.J. Cassidy, C.W. Chung, B.T. Lee, J.E. Common, S.C. Ogg, H. Chen, S.Y. Sim, W.L. Goh, K.W. Ng, J.A. Simpson, L.L. Chee, G.H. Eng, B. Li, D.P. Lunny, D. Chuon, A. Venkatesh, K.H. Khoo, W.H. McLean, Y.P. Lim, E.B. Lane, The human intermediate filament database: comprehensive information on a gene family involved in many human diseases. Hum. Mutat. 29, 351–360 (2008)

    CAS  PubMed  Article  Google Scholar 

  8. A. Satelli, S. Li, Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell. Mol. Life Sci. 68, 3033–3046 (2011)

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  9. K. Rottner, J. Faix, S. Bogdan, S. Linder, E. Kerkhoff, Actin assembly mechanisms at a glance. J. Cell Sci. 130, 3427–3435 (2017)

    CAS  PubMed  Article  Google Scholar 

  10. T. Fujii, A.H. Iwane, T. Yanagida, K. Namba, Direct visualization of secondary structures of F-actin by electron cryomicroscopy. Nature 467, 724–728 (2010)

    CAS  PubMed  Article  Google Scholar 

  11. T.Y. Liaw, M.H. Chang, M. Kavallaris, The cytoskeleton as a therapeutic target in childhood acute leukemia: obstacles and opportunities. Curr. Drug Targets 8, 739–749 (2007)

    CAS  PubMed  Article  Google Scholar 

  12. C. Thiele, G. Hirschfeld, cutpointr: Improved estimation and validation of optimal cutpoints in R. arXiv:2002.09209 (2020)

  13. P.J. Heagerty, Y. Zheng, Survival model predictive accuracy and ROC curves. Biometrics 61, 92–105 (2005)

    PubMed  Article  Google Scholar 

  14. E. Cerami, J. Gao, U. Dogrusoz, B.E. Gross, S.O. Sumer, B.A. Aksoy, A. Jacobsen, C.J. Byrne, M.L. Heuer, E. Larsson, Y. Antipin, B. Reva, A.P. Goldberg, C. Sander, N. Schultz, The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404 (2012)

    PubMed  Article  Google Scholar 

  15. J. Gao, B.A. Aksoy, U. Dogrusoz, G. Dresdner, B. Gross, S.O. Sumer, Y. Sun, A. Jacobsen, R. Sinha, E. Larsson, E. Cerami, C. Sander, N. Schultz, Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013)

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  16. A.R. Lucena-Araujo, J.L. Coelho-Silva, D.A. Pereira-Martins, D.R. Silveira, L.C. Koury, R.A.M. Melo, R. Bittencourt, K. Pagnano, R. Pasquini, E.C. Nunes, E.M. Fagundes, A.B. Gloria, F. Kerbauy, M. de Lourdes Chauffaille, I. Bendit, V. Rocha, A. Keating, M.S. Tallman, R.C. Ribeiro, R. Dillon, A. Ganser, B. Lowenberg, P.J.M. Valk, F. Lo-Coco, M.A. Sanz, N. Berliner, E.M. Rego, Combining gene mutation with gene expression analysis improves outcome prediction in acute promyelocytic leukemia. Blood 134, 951–959 (2019)

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  17. W. Sauerbrei, M. Schumacher, A bootstrap resampling procedure for model building: application to the Cox regression model. Stat. Med. 11, 2093–2109 (1992)

    CAS  PubMed  Article  Google Scholar 

  18. A. Subramanian, P. Tamayo, V.K. Mootha, S. Mukherjee, B.L. Ebert, M.A. Gillette, A. Paulovich, S.L. Pomeroy, T.R. Golub, E.S. Lander, J.P. Mesirov, Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U. S. A. 102, 15545–15550 (2005)

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  19. T.L. Carrour, S. Assou, S. Tondeur, L. Lhermitte, N. Lamb, T. Reme, V. Pantesco, S. Hamamah, B. Klein, J. De Vos, Amazonia!: An online resource to google and visualize public human whole genome expression data. Open Bioinform. J. 4, 5–10 (2010)

    Article  CAS  Google Scholar 

  20. H. Dohner, E. Estey, D. Grimwade, S. Amadori, F.R. Appelbaum, T. Buchner, H. Dombret, B.L. Ebert, P. Fenaux, R.A. Larson, R.L. Levine, F. Lo-Coco, T. Naoe, D. Niederwieser, G.J. Ossenkoppele, M. Sanz, J. Sierra, M.S. Tallman, H.F. Tien, A.H. Wei, B. Lowenberg, C.D. Bloomfield, Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129, 424–447 (2017)

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  21. K.J. Livak, T.D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25, 402–408 (2001)

    CAS  PubMed  Article  Google Scholar 

  22. A.I. Saeed, V. Sharov, J. White, J. Li, W. Liang, N. Bhagabati, J. Braisted, M. Klapa, T. Currier, M. Thiagarajan, A. Sturn, M. Snuffin, A. Rezantsev, D. Popov, A. Ryltsov, E. Kostukovich, I. Borisovsky, Z. Liu, A. Vinsavich, V. Trush, J. Quackenbush, TM4: a free, open-source system for microarray data management and analysis. Biotechniques 34, 374–378 (2003)

    CAS  PubMed  Article  Google Scholar 

  23. G. Bulut, S.H. Hong, K. Chen, E.M. Beauchamp, S. Rahim, G.W. Kosturko, E. Glasgow, S. Dakshanamurthy, H.S. Lee, I. Daar, J.A. Toretsky, C. Khanna, A. Uren, Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells. Oncogene 31, 269–281 (2012)

    CAS  PubMed  Article  Google Scholar 

  24. A. Ghaffari, V. Hoskin, G. Turashvili, S. Varma, J. Mewburn, G. Mullins, P.A. Greer, F. Kiefer, A.G. Day, Y. Madarnas, S. SenGupta, B.E. Elliott, Intravital imaging reveals systemic ezrin inhibition impedes cancer cell migration and lymph node metastasis in breast cancer. Breast Cancer Res. 21, 12 (2019)

    PubMed  PubMed Central  Article  Google Scholar 

  25. H. Celik, S.H. Hong, D.D. Colon-Lopez, J. Han, Y.S. Kont, T.Z. Minas, M. Swift, M. Paige, E. Glasgow, J.A. Toretsky, J. Bosch, A. Uren, Identification of novel ezrin inhibitors targeting metastatic osteosarcoma by screening open access malaria box. Mol. Cancer Ther. 14, 2497–2507 (2015)

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  26. A. Corcoran, T.G. Cotter, FLT3-driven redox-modulation of Ezrin regulates leukaemic cell migration. Free Radic. Res. 47, 20–34 (2013)

    CAS  PubMed  Article  Google Scholar 

  27. R. Monni, L. Haddaoui, A. Naba, I. Gallais, M. Arpin, P. Mayeux, F. Moreau-Gachelin, Ezrin is a target for oncogenic Kit mutants in murine erythroleukemia. Blood 111, 3163–3172 (2008)

    CAS  PubMed  Article  Google Scholar 

  28. G. Habif, M.F. Grasset, S. Kieffer-Jaquinod, L. Kuhn, G. Mouchiroud, S. Gobert-Gosse, Phosphoproteome analyses reveal specific implications of Hcls1, p21-activated kinase 1 and Ezrin in proliferation of a myeloid progenitor cell line downstream of wild-type and ITD mutant Fms-like tyrosine kinase 3 receptors. J. Proteomics 78, 231–244 (2013)

    CAS  PubMed  Article  Google Scholar 

  29. K. Krishnan, B. Bruce, S. Hewitt, D. Thomas, C. Khanna, L.J. Helman, Ezrin mediates growth and survival in Ewing’s sarcoma through the AKT/mTOR, but not the MAPK, signaling pathway. Clin. Exp. Metastasis 23, 227–236 (2006)

    CAS  PubMed  Article  Google Scholar 

  30. E.H. Estey, Treatment of acute myeloid leukemia. Haematologica 94, 10–16 (2009)

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  31. K. Dohner, P. Paschka, Intermediate-risk acute myeloid leukemia therapy: current and future. Hematology Am. Soc. Hematol. Educ. Program 2014, 34–43 (2014)

    PubMed  Article  Google Scholar 

  32. Y. Ofran, J.M. Rowe, Genetic profiling in acute myeloid leukaemia–where are we and what is its role in patient management. Br. J. Haematol. 160, 303–320 (2013)

    CAS  PubMed  Article  Google Scholar 

  33. A. Bretscher, D. Reczek, M. Berryman, Ezrin: a protein requiring conformational activation to link microfilaments to the plasma membrane in the assembly of cell surface structures. J. Cell Sci. 110(Pt 24), 3011–3018 (1997)

    CAS  PubMed  Article  Google Scholar 

  34. K. Kawaguchi, S. Yoshida, R. Hatano, S. Asano, Pathophysiological roles of Ezrin/Radixin/Moesin proteins. Biol. Pharm. Bull. 40, 381–390 (2017)

    CAS  PubMed  Article  Google Scholar 

  35. A.L. Neisch, R.G. Fehon, Ezrin, Radixin and Moesin: key regulators of membrane-cortex interactions and signaling. Curr. Opin. Cell Biol. 23, 377–382 (2011)

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  36. N. Li, J. Kong, Z. Lin, Y. Yang, T. Jin, M. Xu, J. Sun, L. Chen, Ezrin promotes breast cancer progression by modulating AKT signals. Br. J. Cancer 120, 703–713 (2019)

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  37. Y. Song, X. Ma, M. Zhang, M. Wang, G. Wang, Y. Ye, W. Xia, Ezrin mediates invasion and metastasis in tumorigenesis: A review. Front. Cell. Dev. Biol. 8, 588801 (2020)

    PubMed  PubMed Central  Article  Google Scholar 

  38. J. Li, K. Wei, H. Yu, D. Jin, G. Wang, B. Yu, Prognostic value of Ezrin in various cancers: A systematic review and updated meta-analysis. Sci. Rep. 5, 17903 (2015)

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  39. B. Zhou, J. Leng, M. Hu, L. Zhang, Z. Wang, D. Liu, X. Tong, B. Yu, Y. Hu, C. Deng, Y. Liu, Q. Zhang, Ezrin is a key molecule in the metastasis of MOLT4 cells induced by CCL25/CCR9. Leuk. Res. 34, 769–776 (2010)

    CAS  PubMed  Article  Google Scholar 

  40. H. Quentmeier, J. Reinhardt, M. Zaborski, H.G. Drexler, FLT3 mutations in acute myeloid leukemia cell lines. Leukemia 17, 120–124 (2003)

    CAS  PubMed  Article  Google Scholar 

  41. A. Beghini, I. Magnani, C.B. Ripamonti, L. Larizza, Amplification of a novel c-Kit activating mutation Asn(822)-Lys in the Kasumi-1 cell line: a t(8;21)-Kit mutant model for acute myeloid leukemia. Hematol. J. 3, 157–163 (2002)

    CAS  PubMed  Article  Google Scholar 

  42. B. Lowenberg, W.L. van Putten, I.P. Touw, R. Delwel, V. Santini, Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia. N. Engl. J. Med. 328, 614–619 (1993)

    CAS  PubMed  Article  Google Scholar 

  43. D. Pore, J. Bodo, A. Danda, D. Yan, J.G. Phillips, D. Lindner, B.T. Hill, M.R. Smith, E.D. Hsi, N. Gupta, Identification of Ezrin-Radixin-Moesin proteins as novel regulators of pathogenic B-cell receptor signaling and tumor growth in diffuse large B-cell lymphoma. Leukemia 29, 1857–1867 (2015)

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  44. H. Celik, G. Bulut, J. Han, G.T. Graham, T.Z. Minas, E.J. Conn, S.H. Hong, G.T. Pauly, M. Hayran, X. Li, M. Ozdemirli, A. Ayhan, M.A. Rudek, J.A. Toretsky, A. Uren, Ezrin inhibition up-regulates stress response gene expression. J. Biol. Chem. 291, 13257–13270 (2016)

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  45. Y. Tang, X. Sun, S. Yu, X. Bie, J. Wang, L. Ren, Inhibition of Ezrin suppresses cell migration and invasion in human nasopharyngeal carcinoma. Oncol. Lett. 18, 553–560 (2019)

    CAS  PubMed  PubMed Central  Google Scholar 

  46. X. Wan, A. Mendoza, C. Khanna, L.J. Helman, Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res. 65, 2406–2411 (2005)

    CAS  PubMed  Article  Google Scholar 

  47. C.H. Brandts, B. Sargin, M. Rode, C. Biermann, B. Lindtner, J. Schwable, H. Buerger, C. Muller-Tidow, C. Choudhary, M. McMahon, W.E. Berdel, H. Serve, Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Cancer Res. 65, 9643–9650 (2005)

    CAS  PubMed  Article  Google Scholar 

  48. L. Larizza, I. Magnani, A. Beghini, The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia. Leuk. Lymphoma 46, 247–255 (2005)

    CAS  PubMed  Article  Google Scholar 

  49. Y. Tabe, A. Tafuri, K. Sekihara, H. Yang, M. Konopleva, Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia. Expert. Opin. Ther. Targets 21, 705–714 (2017)

    CAS  PubMed  Article  Google Scholar 

  50. S. Darici, H. Alkhaldi, G. Horne, H.G. Jorgensen, S. Marmiroli, X. Huang, Targeting PI3K/Akt/mTOR in AML: Rationale and clinical evidence. J. Clin. Med. 9, 2934 (2020)

  51. I. Nepstad, K.J. Hatfield, I.S. Gronningsaeter, H. Reikvam, The PI3K-Akt-mTOR signaling pathway in human acute myeloid leukemia (AML) cells. Int. J. Mol. Sci. 21, 2907 (2020)

  52. M. Ingham, G.K. Schwartz, Cell-cycle therapeutics come of age. J. Clin. Oncol. 35, 2949–2959 (2017)

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  53. M.P. Luna-Vargas, J.E. Chipuk, The deadly landscape of pro-apoptotic BCL-2 proteins in the outer mitochondrial membrane. FEBS J. 283, 2676–2689 (2016)

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  54. W.A. Siddiqui, A. Ahad, H. Ahsan, The mystery of BCL2 family: Bcl-2 proteins and apoptosis: an update. Arch. Toxicol. 89, 289–317 (2015)

    CAS  PubMed  Article  Google Scholar 

  55. H.E. Ramsey, M.A. Fischer, T. Lee, A.E. Gorska, M.P. Arrate, L. Fuller, K.L. Boyd, S.A. Strickland, J. Sensintaffar, L.J. Hogdal, G.D. Ayers, E.T. Olejniczak, S.W. Fesik, M.R. Savona, A novel MCL1 inhibitor combined with Venetoclax rescues Venetoclax-resistant acute myelogenous leukemia. Cancer Discov. 8, 1566–1581 (2018)

    CAS  PubMed  PubMed Central  Article  Google Scholar 

Download references

Acknowledgements

The authors thank Dr. Gabriela Sarti Kinker for providing assistance with the GSEA analysis. The authors also would like to acknowledge all the research participants contributing to The Cancer Genome Atlas (TCGA) resource for providing high quality data for analysis.

Funding

This study was supported by grants #2017/24993-0, #2019/23864-7 and #2015/17177-6 from the São Paulo Research Foundation (FAPESP). This study was also financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES) - Finance Code 001.

Author information

Authors and Affiliations

  1. Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, Av. Prof. Lineu Prestes, 1524, CEP 05508-900, São Paulo, SP, Brazil

    Jean Carlos Lipreri da Silva, Keli Lima, Hugo Passos Vicari, Leticia Veras Costa-Lotufo & João Agostinho Machado-Neto

  2. Department of Medical Imaging, Hematology, and Oncology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil

    Juan Luiz Coelho-Silva & Fabiola Traina

  3. Department of Pharmaceutical Sciences, Federal University of São Paulo, Diadema, Brazil

    Mariana Lazarini

Authors
  1. Jean Carlos Lipreri da Silva
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Juan Luiz Coelho-Silva
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Keli Lima
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hugo Passos Vicari
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mariana Lazarini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Leticia Veras Costa-Lotufo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Fabiola Traina
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. João Agostinho Machado-Neto
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

J.C.L.S. conception and design, execution of experiments, data analysis and interpretation, and manuscript writing, J.L.C.-S., H.P.V. and K.L. conception and design, data analysis and interpretation, and manuscript editing. M.L., L.V.C.-L. and F.T. data analysis and interpretation, and manuscript writing. J.A.M.-N. conception and design, data analysis and interpretation, manuscript writing and gave final approval of the manuscript. All authors read and approved the final version of the manuscript.

Corresponding author

Correspondence to João Agostinho Machado-Neto.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Conflict of interest disclosure

The authors declare no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

ESM 1

(DOC 36.0 KB)

ESM 2

(DOC 185 KB)

ESM 3

(DOC 175 KB)

ESM 4

(DOC 35.5 KB)

ESM 5

(DOC 26.5 KB)

ESM 6

(DOC 396 KB)

ESM 7

(DOC 40.0 KB)

ESM 8

(DOC 48.5 KB)

ESM 9

(DOC 1.55 MB)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Lipreri da Silva, J.C., Coelho-Silva, J.L., Lima, K. et al. Comprehensive analysis of cytoskeleton regulatory genes identifies ezrin as a prognostic marker and molecular target in acute myeloid leukemia. Cell Oncol. 44, 1105–1117 (2021). https://doi.org/10.1007/s13402-021-00621-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13402-021-00621-0

Keywords

  • Acute myeloid leukemia
  • Cytoskeleton
  • Antineoplastic agents
  • Ezrin